Danaher (NYSE:DHR) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Danaher (NYSE:DHR) released its quarterly earnings results on Tuesday. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20, Briefing.com reports. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the previous year, the firm posted $2.36 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year.

Danaher Price Performance

NYSE DHR traded down $4.31 on Wednesday, reaching $248.80. 1,039,306 shares of the stock traded hands, compared to its average volume of 2,754,582. The firm’s fifty day simple moving average is $248.95 and its 200 day simple moving average is $230.64. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The company has a market cap of $184.25 billion, a price-to-earnings ratio of 39.74, a P/E/G ratio of 3.96 and a beta of 0.83. Danaher has a 12 month low of $182.09 and a 12 month high of $259.00.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

Analysts Set New Price Targets

Several research firms recently commented on DHR. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. KeyCorp boosted their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Royal Bank of Canada boosted their price target on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Raymond James upped their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $268.00.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 3,289 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,957 shares of company stock valued at $8,265,802. 10.90% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.